Evidence map›Paper›PMID 32231305›Full record

ArticleNature cell biology2020

Netrin-1 promotes naive pluripotency through Neo1 and Unc5b co-regulation of Wnt and MAPK signalling.

Aurélia Huyghe, Giacomo Furlan, Duygu Ozmadenci, Christina Galonska, Jocelyn Charlton, Xavier Gaume, Noémie Combémorel, Christina Riemenschneider, Nicolas Allègre, Jenny Zhang and 13 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Nature cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Novel netrin-1-Unc5b-Klf4 axis balances AT2 survival in experimental bronchopulmonary dysplasia.American journal of respiratory cell and molecular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Epigenetic Regulation of DAPK1 and Netrin-1 Drives Diabetic Encephalopathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Aurélia Huyghe *Cellular Reprogramming and Oncogenesis Laboratory, Equipe labellisée la Ligue contre le cancer, Labex DEVweCAN, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Giacomo Furlan *Cellular Reprogramming and Oncogenesis Laboratory, Equipe labellisée la Ligue contre le cancer, Labex DEVweCAN, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Duygu Ozmadenci *Cellular Reprogramming and Oncogenesis Laboratory, Equipe labellisée la Ligue contre le cancer, Labex DEVweCAN, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Christina GalonskaDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Jocelyn CharltonDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Xavier GaumeCellular Reprogramming and Oncogenesis Laboratory, Equipe labellisée la Ligue contre le cancer, Labex DEVweCAN, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Noémie CombémorelCellular Reprogramming and Oncogenesis Laboratory, Equipe labellisée la Ligue contre le cancer, Labex DEVweCAN, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Christina RiemenschneiderDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Nicolas AllègreGReD, Université Clermont Auvergne, CNRS, INSERM, BP38, Clermont-Ferrand, France.
Jenny ZhangDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, USA.
Pauline WajdaCellular Reprogramming and Oncogenesis Laboratory, Equipe labellisée la Ligue contre le cancer, Labex DEVweCAN, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Nicolas RamaApoptosis, Cancer and Development Laboratory, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Pauline VieuguéApoptosis, Cancer and Development Laboratory, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Isabelle DurandCytometry Facility, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, INSERM 1052, CNRS 5286, Lyon, France.
Marie BrevetResearch Pathology platform, Department of translational research and innovation, Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0003-2275-691X
Nicolas GadotResearch Pathology platform, Department of translational research and innovation, Centre Léon Bérard, Lyon, France.
Thomas ImhofInstitute for Dental Research and Oral Musculoskeletal Research, Center for Biochemistry, University of Cologne, Cologne, Germany.
Bradley J MerrillDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-5074-3345
Manuel KochInstitute for Dental Research and Oral Musculoskeletal Research, Center for Biochemistry, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-2962-7814
Patrick MehlenApoptosis, Cancer and Development Laboratory, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Claire ChazaudGReD, Université Clermont Auvergne, CNRS, INSERM, BP38, Clermont-Ferrand, France.
Alexander MeissnerDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.ORCID http://orcid.org/0000-0001-8646-7469
Fabrice LavialCellular Reprogramming and Oncogenesis Laboratory, Equipe labellisée la Ligue contre le cancer, Labex DEVweCAN, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France. fabrice.lavial@lyon.unicancer.fr.ORCID http://orcid.org/0000-0001-9752-4393
Université Claude Bernard Lyon 1 · FRBroad Institute · USCentre Léon Bérard · FRCentre National de la Recherche Scientifique · FRMax Planck Institute for Molecular Genetics · DEUniversity of Cologne · DEUniversity of Illinois Chicago · US

Funding

Wnt/Beta-catenin and Tcf/Lef factor regulation of pluripotencyR01HD081534 · NICHD · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MERRILL, BRADLEY J · 2014 to 2018
$1.6M
NICHD NIH HHS R01 HD081534
6 · The paper itself

Abstract

In mouse embryonic stem cells (mESCs), chemical blockade of Gsk3α/β and Mek1/2 (2i) instructs a self-renewing ground state whose endogenous inducers are unknown. Here we show that the axon guidance cue Netrin-1 promotes naive pluripotency by triggering profound signalling, transcriptomic and epigenetic changes in mESCs. Furthermore, we demonstrate that Netrin-1 can substitute for blockade of Gsk3α/β and Mek1/2 to sustain self-renewal of mESCs in combination with leukaemia inhibitory factor and regulates the formation of the mouse pluripotent blastocyst. Mechanistically, we reveal how Netrin-1 and the balance of its receptors Neo1 and Unc5B co-regulate Wnt and MAPK pathways in both mouse and human ESCs. Netrin-1 induces Fak kinase to inactivate Gsk3α/β and stabilize β-catenin while increasing the phosphatase activity of a Ppp2r2c-containing Pp2a complex to reduce Erk1/2 activity. Collectively, this work identifies Netrin-1 as a regulator of pluripotency and reveals that it mediates different effects in mESCs depending on its receptor dosage, opening perspectives for balancing self-renewal and lineage commitment.

Indexed as

Gene Expression Regulation, DevelopmentalAnimalsbeta CateninCell LineEmbryo, MammalianExtracellular Signal-Regulated MAP KinasesFocal Adhesion Kinase 1Glycogen Synthase Kinase 3 betaHumansIsoenzymesLeukemia Inhibitory FactorMaleMAP Kinase Kinase 1MAP Kinase Kinase 2MiceMice, Knockoutbeta CateninCTNNB1 protein, mouseExtracellular Signal-Regulated MAP KinasesFocal Adhesion Kinase 1Glycogen Synthase Kinase 3 betaGsk3b protein, mouseIsoenzymesLeukemia Inhibitory FactorLif protein, mouseMap2k1 protein, mouseMap2k2 protein, mouseMAP Kinase Kinase 1MAP Kinase Kinase 2NEO1 protein, humanNerve Tissue ProteinsNetrin-1Netrin ReceptorsNtn1 protein, mousePPP2R2C protein, humanProtein Phosphatase 2Ptk2 protein, mouseReceptors, Cell SurfaceUNC5B protein, humanUnc5b protein, mouse

Identifiers

PMID32231305
OpenAlexW3013180179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.